Regenxbio (RGNX) Current Leases (2019 - 2025)

Regenxbio's Current Leases history runs 7 years deep, the most recent figure standing at $8.3 million for Q4 2025.

• In Q4 2025, Current Leases rose 4.86% year-over-year to $8.3 million; the TTM figure through Dec 2025 stood at $8.3 million (up 4.86% YoY), while the FY2025 annual figure was $8.3 million, up 4.86% from the prior year.
• Current Leases was $8.3 million for Q4 2025 at Regenxbio, down from $9.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $9.1 million in Q3 2025 to a low of $1.3 million in Q3 2021.
• Historically, Current Leases has averaged $5.5 million across 5 years, with a median of $6.5 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Current Leases plunged 62.71% in 2021, then surged 242.29% in 2022.
• A 5-year view of Current Leases shows it stood at $1.8 million in 2021, then soared by 242.29% to $6.0 million in 2022, then climbed by 17.86% to $7.1 million in 2023, then increased by 11.8% to $7.9 million in 2024, then grew by 4.86% to $8.3 million in 2025.
• The last three Current Leases figures came in at $8.3 million (Q4 2025), $9.1 million (Q3 2025), and $8.0 million (Q2 2025), per Business Quant data.